SYNTHESES AND CELLULAR STUDIES OF NEW PHOTOSENSITIZERS FOR MEDICAL APPLICATIONS
新型医疗应用光敏剂的合成和细胞研究
基本信息
- 批准号:8387759
- 负责人:
- 金额:$ 27.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-01-01 至 2014-11-30
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAge related macular degenerationAlkenesAmino AcidsApoptosisApoptoticAreaArterial Fatty StreakAtherosclerosisAutophagocytosisBCL2 geneBehaviorBiochemicalBiologicalBiological feedbackBloodBlood TransfusionBone MarrowBone Marrow PurgingCardiovascular DiseasesCardiovascular systemCattleCause of DeathCell DeathCellsCessation of lifeCharacteristicsClinicClinicalClinical TrialsComplexDetectionDevelopmentDiagnosisDiseaseDoseDrug DesignEquilibriumEventExposure toFDA approvedGenerationsGoalsHousingHumanIntentionInvestigationIsomerismKineticsKnowledgeLengthLightMacular degenerationMalignant NeoplasmsMedicalMedicineMetalsMethodsMitochondriaModalityModificationMono-SNecrosisOrganellesOrganic SynthesisOxygenPatientsPeptidesPharmaceutical PreparationsPhotochemotherapyPhotosensitivityPhotosensitizationPhotosensitizing AgentsPhototoxicityPolyethylene GlycolsPorfimer SodiumPorphyrinsPrion DiseasesProductionPropertyProtein FamilyPublic HealthReactionRelative (related person)ReportingResearchResidual stateRouteScrapieSeriesSheepSinglet OxygenSiteSkinSpecificityStructureStructure-Activity RelationshipTaporfin SodiumTetrapyrrolesTimeTissuesToxic effectTransfusionTreatment EfficacyTumor TissueVariantVerteporfinViralVirusWorkabsorptionamphiphilicitybasecancer therapycellular targetingchlorinchlorin e6chromophorecytotoxiccytotoxicitydesigndrug developmentimprovedin vivomonoaspartyl chlorin e6neoplastic cellphthalocyanineporphyceneprogramspublic health relevancesuccesstumoruptake
项目摘要
DESCRIPTION (provided by applicant): This proposal focuses on the design, synthesis, development and optimization of promising tetrapyrrole photodynamic therapy (PDT) photosensitizers for use in diagnosis and treatment of cancer and age-related macular degeneration, for use against atherosclerotic lesions, in virus eradication from blood, bone marrow purging, and for inhibition of transmissible spongiform encephalopathies [bovine (BSE), sheep (scrapie) and human forms (Creutzfeld-Jacob disease)]. PDT is a binary therapy involving light-activation of a photosensitizer that has been targeted to specific cells. This results in the generation of singlet oxygen and other cytotoxic species that cause disease cell destruction while sparing healthy tissues. There are only two FDA-approved tetrapyrrole photosensitizers - Photofrin and Visudyne; both of these drugs are mixtures of compounds with limited selectivity for tumor tissue. It is proposed to develop new efficient organic synthesis methods to three types of tetrapyrrole photosensitizer: amino acid, peptide, and polyethylene glycol (PEG) conjugates of (1) chlorin e6, (2) isoporphyrins, and (3) benzoporphyrins and porphycenes. For the most part, the aim is to prepare cell- and specific organelle-targeted photosensitizers for the PDT treatment of diseased cells and plaque. The tetrapyrrole photosensitizers that are synthesized will be directed to specific organelles (preferably the mitochondria) by conjugation with one or more amino acid, short peptide, or PEG of defined length. Sufficient examples within any series of synthetic sensitizers will permit the investigation of mechanisms of cellular uptake, intracellular localization and cytotoxicity. Modes of cell death for the most promising sensitizers will also be determined. This research will result in structure/activity relationships that are crucial in the design and development of better and more effective PDT photosensitizers for use in cancer, cardiovascular, blood transfusion, bone marrow purging, and spongiform encephalopathy areas of medicine. Extensive preliminary studies have been completed and show viability of all aspects of the proposed research. The new drugs will also be investigated in house for cellular uptake, intracellular localization and dark/light toxicity, and with a consultant for modes of cell death (promoting apoptosis over necrosis); rapid modifications of approach will be possible based on feedback from the biological work. It will be possible to balance biochemical and physicochemical characteristics of drugs with their PDT efficacy, and to use mechanistic knowledge to develop more effective PDT sensitizers. It is intended to understand the mechanisms of cellular targeting, uptake and subcellular localization of new tetrapyrrole sensitizers and to develop new highly effective drugs for medical use.
描述(申请人提供):该提案集中于设计、合成、开发和优化有前景的四吡咯光动力疗法(PDT)光敏剂,用于诊断和治疗癌症和年龄相关性黄斑变性,用于抗动脉粥样硬化病变,用于从血液中根除病毒,骨髓净化,以及用于抑制传染性海绵状脑病[牛(BSE),绵羊(羊瘙痒病)和人类形式(克雅氏病)]。PDT是一种二元疗法,涉及针对特定细胞的光敏剂的光激活。这导致单线态氧和其他细胞毒性物质的产生,这些物质导致疾病细胞破坏,同时保护健康组织。只有两种FDA批准的四吡咯光敏剂- Photofrin和Visudyne;这两种药物都是对肿瘤组织选择性有限的化合物的混合物。本文提出了三种四吡咯光敏剂:(1)二氢卟啉e6,(2)异卟啉,(3)苯并卟啉和卟啉的氨基酸、肽和聚乙二醇(PEG)共轭物的有机合成新方法。在大多数情况下,目的是制备细胞和特定细胞器靶向的光敏剂,用于病变细胞和斑块的PDT治疗。所合成的四吡咯光敏剂将通过与一个或多个氨基酸、短肽或限定长度的PEG缀合而导向特定的细胞器(优选线粒体)。任何系列合成致敏剂中的足够例子将允许研究细胞摄取、细胞内定位和细胞毒性的机制。还将确定最有希望的致敏剂的细胞死亡模式。这项研究将导致结构/活性关系,这对于设计和开发更好,更有效的PDT光敏剂用于癌症,心血管,输血,骨髓净化和海绵状脑病医学领域至关重要。广泛的初步研究已经完成,并显示拟议研究的各个方面的可行性。还将在内部研究新药的细胞摄取,细胞内定位和暗/光毒性,并与顾问一起研究细胞死亡模式(促进细胞凋亡而不是坏死);根据生物学工作的反馈,可以快速修改方法。这将有可能平衡药物的生化和物理化学特性与其PDT功效,并使用机制知识来开发更有效的PDT增敏剂。其目的是了解新的四吡咯敏化剂的细胞靶向、摄取和亚细胞定位的机制,并开发用于医疗用途的新的高效药物。
项目成果
期刊论文数量(29)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Functionalization of 3,5,8-trichlorinated BODIPY dyes.
- DOI:10.1021/jo501969z
- 发表时间:2014-11-07
- 期刊:
- 影响因子:0
- 作者:Wang H;Fronczek FR;Vicente MG;Smith KM
- 通讯作者:Smith KM
Functionalization of the corrole ring: the role of isocorrole intermediates.
咔咯环的功能化:异咔咯中间体的作用。
- DOI:10.1039/c0cc05837h
- 发表时间:2011
- 期刊:
- 影响因子:0
- 作者:Tortora,Luca;Nardis,Sara;Fronczek,FrankR;Smith,KevinM;Paolesse,Roberto
- 通讯作者:Paolesse,Roberto
β-Nitro derivatives of iron corrolates.
- DOI:10.1021/ic3002459
- 发表时间:2012-03-19
- 期刊:
- 影响因子:4.6
- 作者:Nardis S;Stefanelli M;Mohite P;Pomarico G;Tortora L;Manowong M;Chen P;Kadish KM;Fronczek FR;McCandless GT;Smith KM;Paolesse R
- 通讯作者:Paolesse R
Syntheses of protoporphyrin-IX derivatives bearing extended propionate side-chains.
带有延伸丙酸酯侧链的原卟啉-IX 衍生物的合成。
- DOI:10.1901/jaba.2009.2010-5
- 发表时间:2009
- 期刊:
- 影响因子:0
- 作者:Holmes,RobertT;Lu,Jianming;Mwakwari,Celinah;Smith,KevinM
- 通讯作者:Smith,KevinM
Copper β-trinitrocorrolates.
铜β-三硝基corrolates。
- DOI:10.1142/s1088424613500120
- 发表时间:2013
- 期刊:
- 影响因子:1.5
- 作者:Stefanelli,Manuela;Nardis,Sara;Fronczek,FrankR;Smith,KevinM;Paolesse,Roberto
- 通讯作者:Paolesse,Roberto
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kevin M Smith其他文献
Syntheses of some β-substituted alkyne porphyrins related to protoporphyrin-IX
与原卟啉-IX相关的一些β-取代炔卟啉的合成
- DOI:
- 发表时间:
1996 - 期刊:
- 影响因子:0
- 作者:
Xuqin Jiang;Kevin M Smith - 通讯作者:
Kevin M Smith
Synthetic approaches to long-wavelength photosensitizers for photodynamic therapy
用于光动力治疗的长波长光敏剂的合成方法
- DOI:
- 发表时间:
1991 - 期刊:
- 影响因子:0
- 作者:
F. Shiau;R. Pandey;T. Dougherty;Kevin M Smith - 通讯作者:
Kevin M Smith
NMR spectra of porphyrins. 28. Detailed solution structure of a bacteriochlorophyllide d dimer
卟啉的核磁共振谱。
- DOI:
10.1021/ja00266a001 - 发表时间:
1986 - 期刊:
- 影响因子:15
- 作者:
Kevin M Smith;F. Bobe;D. Goff;R. J. Abraham - 通讯作者:
R. J. Abraham
Red shift of absorption maxima in chlorobiineae through enzymic methylation of their antenna bacteriochlorophylls.
通过触角细菌叶绿素的酶促甲基化,绿二亚科的吸收最大值发生红移。
- DOI:
10.1021/bi00470a012 - 发表时间:
1990 - 期刊:
- 影响因子:2.9
- 作者:
F. Bobe;N. Pfennig;K. L. Swanson;Kevin M Smith - 通讯作者:
Kevin M Smith
3.07 – Porphyrins, Corrins and Phthalocyanines
- DOI:
10.1016/b978-008096519-2.00057-6 - 发表时间:
1984 - 期刊:
- 影响因子:0
- 作者:
Kevin M Smith - 通讯作者:
Kevin M Smith
Kevin M Smith的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kevin M Smith', 18)}}的其他基金
SYNTHESES AND CELLULAR STUDIES OF NEW PHOTOSENSITIZERS FOR MEDICAL APPLICATIONS
新型医疗应用光敏剂的合成和细胞研究
- 批准号:
7993596 - 财政年份:2009
- 资助金额:
$ 27.81万 - 项目类别:
SYNTHESES AND CELLULAR STUDIES OF NEW PHOTOSENSITIZERS FOR MEDICAL APPLICATIONS
新型医疗应用光敏剂的合成和细胞研究
- 批准号:
7582084 - 财政年份:2009
- 资助金额:
$ 27.81万 - 项目类别:
SYNTHESES AND CELLULAR STUDIES OF NEW PHOTOSENSITIZERS FOR MEDICAL APPLICATIONS
新型医疗应用光敏剂的合成和细胞研究
- 批准号:
8197646 - 财政年份:2009
- 资助金额:
$ 27.81万 - 项目类别:
SYNTHESES AND CELLULAR STUDIES OF NEW PHOTOSENSITIZERS FOR MEDICAL APPLICATIONS
新型医疗应用光敏剂的合成和细胞研究
- 批准号:
7753191 - 财政年份:2009
- 资助金额:
$ 27.81万 - 项目类别:
SYNTHESES OF LABELED HEMES FOR PROTEIN NMR STUDIES
用于蛋白质 NMR 研究的标记血红素的合成
- 批准号:
3336787 - 财政年份:1992
- 资助金额:
$ 27.81万 - 项目类别:
SYNTHESES OF LABELED HEMES FOR PROTEIN NMR STUDIES
用于蛋白质 NMR 研究的标记血红素的合成
- 批准号:
3336786 - 财政年份:1992
- 资助金额:
$ 27.81万 - 项目类别:
相似海外基金
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care
I(eye)-SCREEN:基于人工智能的现实基础设施,用于筛查和预测年龄相关性黄斑变性 (AMD) 的进展,提供可及的共享护理
- 批准号:
10102692 - 财政年份:2024
- 资助金额:
$ 27.81万 - 项目类别:
EU-Funded
Inhibiting Neovascularization and Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration
抑制新生血管性年龄相关性黄斑变性的新生血管形成和视网膜下纤维化
- 批准号:
10639785 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
Inhibition of melanogenesis in retinal pigment epithelium, a contributing factor in age-related macular degeneration
抑制视网膜色素上皮中的黑色素生成,这是年龄相关性黄斑变性的一个促成因素
- 批准号:
23K09052 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
- 批准号:
10679287 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
Evaluation of New Anti-inflammatory Treatments for Age-Related Macular Degeneration
年龄相关性黄斑变性的新型抗炎治疗方法的评价
- 批准号:
10642988 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
Progression of Early Atrophic Lesions in Age-related Macular degeneration
年龄相关性黄斑变性早期萎缩性病变的进展
- 批准号:
10635325 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
Cellular and molecular mechanisms of AIM2 and NLRP3 inflammasome activation in age-related macular degeneration
年龄相关性黄斑变性中 AIM2 和 NLRP3 炎症小体激活的细胞和分子机制
- 批准号:
10584110 - 财政年份:2023
- 资助金额:
$ 27.81万 - 项目类别:
Elucidation of roles of mast cells and macrophages in the pathogenesis of age-related macular degeneration
阐明肥大细胞和巨噬细胞在年龄相关性黄斑变性发病机制中的作用
- 批准号:
22H03243 - 财政年份:2022
- 资助金额:
$ 27.81万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
AMD Mitochondria Modulate Expression of microRNA 135b-5p and 148a-3p in RPE Cybrids: Implications for Age-related Macular Degeneration
AMD 线粒体调节 RPE Cybrids 中 microRNA 135b-5p 和 148a-3p 的表达:对年龄相关性黄斑变性的影响
- 批准号:
10433610 - 财政年份:2022
- 资助金额:
$ 27.81万 - 项目类别:
Targeting the inflammatory response in age-related macular degeneration
针对年龄相关性黄斑变性的炎症反应
- 批准号:
10504138 - 财政年份:2022
- 资助金额:
$ 27.81万 - 项目类别: